Ranitidine therapy for esophagitis in children with developmental disabilities.
Esophagitis is common in children with cerebral palsy. Because histamine2-receptor antagonists such as ranitidine have not been uniformly effective, we treated disabled children with esophagitis with greater than usual doses. Endoscopy and pH monitoring were used to monitor dose and response to treatment. A dose of 9.3 +/- 0.9 mg/kg/day did not improve visual or microscopic esophagitis after 3 months. A dose of 14.8 +/- 3.9 mg/kg/day resulted in only slight microscopic improvement, but symptoms were improved. There was no correlation between esophageal reflux index at enrollment and either severity of esophagitis or response to treatment. Elevation of gastric pH by ranitidine was infrequent. These results affirm that pH monitoring does not reliably identify disabled children with reflux esophagitis nor does ranitidine reliably heal this disorder.
Kaufman
S S
SS
Joint Section of Pediatric Gastroenterology, Creighton University, Omaha, NE 68114, USA.
Loseke
C A
CA
Young
R J
RJ
Perry
D A
DA
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D004941:Esophagitis / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D005755:Gastrins / Q000097:blood; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D011899:Ranitidine / Q000008:administration & dosage*
D005755:Gastrins; D011899:Ranitidine